Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,507 JPY | +0.72% | +3.51% | +5.74% |
Mar. 29 | Nakanishi to Sell 8.49 Million Yen Worth of Shares As Restricted Stock Compensation | MT |
Mar. 19 | Nakanishi to Cancel 841,200 Repurchased Shares on April 5 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+5.74% | 1.34B | - | ||
-29.43% | 3.14B | B- | ||
-18.39% | 2.47B | C+ | ||
+12.41% | 2.35B | - | A- | |
+41.48% | 2.14B | B | ||
-1.23% | 2.03B | - | ||
+40.00% | 1.63B | B | ||
+48.11% | 1.29B | C | ||
+9.30% | 1.19B | - | ||
+14.26% | 1.12B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 7716 Stock
- Ratings Nakanishi Inc.